Effects of the psychotomimetic benzomorphan N-allylnormetazocine (SKF 10,047) on prepulse inhibition of startle in mice

[1]  G. Collingridge,et al.  Pharmacological Investigations of the Dissociative ‘Legal Highs’ Diphenidine, Methoxphenidine and Analogues , 2016, PloS one.

[2]  S. Powell,et al.  The novel ketamine analog methoxetamine produces dissociative-like behavioral effects in rodents , 2016, Psychopharmacology.

[3]  F. Vollenweider,et al.  Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects , 2015, Biological Psychiatry.

[4]  J. McLaughlin,et al.  Physical Presence of Nor-Binaltorphimine in Mouse Brain over 21 Days after a Single Administration Corresponds to Its Long-Lasting Antagonistic Effect on κ-Opioid Receptors , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[5]  Matthew W. Johnson,et al.  Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects , 2013, Psychopharmacology.

[6]  B. Cohen,et al.  Dose-Related Behavioral, Subjective, Endocrine, and Psychophysiological Effects of the κ Opioid Agonist Salvinorin A in Humans , 2012, Biological Psychiatry.

[7]  B. Cohen,et al.  Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity , 2012, BMC pharmacology.

[8]  Peter H. Addy.  Acute and post-acute behavioral and psychological effects of salvinorin A in humans , 2011, Psychopharmacology.

[9]  Matthew W. Johnson,et al.  Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. , 2011, Drug and alcohol dependence.

[10]  V. Chefer,et al.  The effects of kappa-opioid receptor ligands on prepulse inhibition and CRF-induced prepulse inhibition deficits in the rat , 2010, Psychopharmacology.

[11]  M. Geyer,et al.  LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor , 2009, Psychopharmacology.

[12]  M. Geyer,et al.  Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis , 2007, Journal of psychopharmacology.

[13]  Yuko Fujita,et al.  Phencyclidine-Induced Cognitive Deficits in Mice are Improved by Subsequent Subchronic Administration of Fluvoxamine: Role of Sigma-1 Receptors , 2007, Neuropsychopharmacology.

[14]  M. Hiramatsu,et al.  Improvement of memory impairment by (+)- and (−)-pentazocine via sigma, but not kappa opioid receptors , 2005, Brain Research.

[15]  G. Gessa,et al.  Kappa Opioid Receptor Activation Disrupts Prepulse Inhibition of the Acoustic Startle in Rats , 2005, Biological Psychiatry.

[16]  M. Geyer,et al.  Parametric determinants in pre-stimulus modification of acoustic startle: interaction with ketamine , 2005, Psychopharmacology.

[17]  E. Butelman,et al.  Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors , 2005, Psychopharmacology.

[18]  M. Geyer,et al.  Dopaminergic stimulation disrupts sensorimotor gating in the rat , 2004, Psychopharmacology.

[19]  D. Segal,et al.  Evidence for multiple opiate receptor involvement in different phencyclidine-induced unconditioned behaviors in rats , 2004, Psychopharmacology.

[20]  E. T. Iwamoto.  Comparison of the pharmacologic effects of N-allylnormetazocine and phencyclidine: Sensitization, cross-sensitization, and opioid antagonist activity , 2004, Psychopharmacology.

[21]  C. Haertzen.  Subjective effects of narcotic antagonists cyclazocine and nalorphine on the Addiction Research Center Inventory (ARCI) , 2004, Psychopharmacologia.

[22]  Teruo Hayashi,et al.  Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. , 2003, Current medicinal chemistry.

[23]  J. Wiley,et al.  Affinity and specificity of N-methyl-D-aspartate channel blockers affect their ability to disrupt prepulse inhibition of acoustic startle in rats , 2003, Psychopharmacology.

[24]  Meyer B. Jackson,et al.  The Sigma Receptor as a Ligand-Regulated Auxiliary Potassium Channel Subunit , 2002, Neuron.

[25]  Franz X Vollenweider,et al.  A systems model of altered consciousness: integrating natural and drug-induced psychoses , 2001, Brain Research Bulletin.

[26]  G. Bigelow,et al.  Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans , 2001, Psychopharmacology.

[27]  G. Pasternak,et al.  Molecular cloning and pharmacological characterization of the rat sigma1 receptor. , 2001, Biochemical pharmacology.

[28]  Erica Duncan,et al.  Clinical and Sensorimotor Gating Effects of Ketamine in Normals , 2001, Neuropsychopharmacology.

[29]  Teruo Hayashi,et al.  Regulating ankyrin dynamics: Roles of sigma-1 receptors. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Tanaka,et al.  Effects of sigma(1) receptor ligand, MS-377 on apomorphine- or phencyclidine-induced disruption of prepulse inhibition of acoustic startle in rats. , 2000, European journal of pharmacology.

[31]  M A Geyer,et al.  Disruption of prepulse inhibition and increases in locomotor activity by competitive N-methyl-D-aspartate receptor antagonists in rats. , 1999, The Journal of pharmacology and experimental therapeutics.

[32]  S. Kulkarni,et al.  Sigma (σ1) receptor mediated antidepressant‐like effects of neurosteroids in the Porsolt forced swim test , 1998 .

[33]  M. Decker,et al.  Effects of phencyclidne (PCP) and (+)MK-801 on sensorimotor gating in CD-1 mice , 1998, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[34]  S. Kulkarni,et al.  Sigma (sigma1) receptor mediated anti-depressant-like effects of neurosteroids in the Porsolt forced swim test. , 1998, Neuroreport.

[35]  Effects of phencyclidine (PCP) and (+)MK-801 on sensorimotor gating in CD-1 mice. , 1998, Progress in neuro-psychopharmacology & biological psychiatry.

[36]  V. Ganapathy,et al.  Cloning and structural analysis of the cDNA and the gene encoding the murine type 1 sigma receptor. , 1997, Biochemical and biophysical research communications.

[37]  J. Witkin,et al.  Dizocilpine-like discriminative stimulus effects of competitive NMDA receptor antagonists in mice , 1997, Psychopharmacology.

[38]  E. Kempner,et al.  Purification, molecular cloning, and expression of the mammalian sigma1-binding site. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Y. Minabe,et al.  Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. , 1996, European journal of pharmacology.

[40]  G. Pasternak,et al.  (−)-Pentazocine analgesia in mice: interactions with a σ receptor system , 1995 .

[41]  M. Pontecorvo,et al.  NPC 16377, a potent and selective sigma-ligand. II. Behavioral and neuroprotective profile. , 1993, The Journal of pharmacology and experimental therapeutics.

[42]  S. Holtzman.  Discriminative stimulus effects of the PCP/σ-ligand (+)-N-Allylnormetazocine in monkeys , 1993, Pharmacology Biochemistry and Behavior.

[43]  S. Holtzman.  Discriminative stimulus effects of the PCP/sigma-ligand (+)-N-allylnormetazocine in monkeys. , 1993, Pharmacology, biochemistry, and behavior.

[44]  J. Woods,et al.  Tolerance to the cataleptic effect of the N-methyl-D-aspartate (NMDA) receptor antagonists in pigeons: cross-tolerance between PCP-like compounds and competitive NMDA antagonists. , 1992, The Journal of pharmacology and experimental therapeutics.

[45]  S. Mascarella,et al.  Enantiomeric N-substituted N-normetazocines: a comparative study of affinities at sigma, PCP, and mu opioid receptors. , 1992, Journal of medicinal chemistry.

[46]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[47]  T. Cicero,et al.  Affinity of drugs and peptides for U-69,593-sensitive and -insensitive kappa opiate binding sites: the U-69,593-insensitive site appears to be the beta endorphin-specific epsilon receptor. , 1990, The Journal of pharmacology and experimental therapeutics.

[48]  J. Vignon,et al.  In vivo labeling of phencyclidine (PCP) receptors with 3H‐TCP in the mouse brain , 1990, Journal of neuroscience research.

[49]  J. Musacchio.  The psychotomimetic effects of opiates and the sigma receptor. , 1990, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[50]  E. Wong,et al.  Evidence against an involvement of the haloperidol‐sensitive σ recognition site in the discriminative stimulus properties of (+)‐N‐allylnormetazocine ((+)‐SKF 10,047) , 1990, British journal of pharmacology.

[51]  G. Ma,et al.  Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. , 1989 .

[52]  W. Bowen,et al.  Synthesis and evaluation of optically pure [3H]‐(+)‐pentazocine, a highly potent and selective radioligand for σ receptors , 1989 .

[53]  D. Sanger,et al.  The discriminative stimulus effects of MK-801: Generalization to other N-methyl-D-aspartate receptor antagonists , 1989, Journal of psychopharmacology.

[54]  R. Balster.  Substitution and antagonism in rats trained to discriminate (+)-N-allylnormetazocine from saline. , 1989, The Journal of pharmacology and experimental therapeutics.

[55]  W. Bowen,et al.  Synthesis and evaluation of optically pure [3H]-(+)-pentazocine, a highly potent and selective radioligand for sigma receptors. , 1989, FEBS letters.

[56]  M. Geyer,et al.  Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. , 1989, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[57]  S. M. Owens,et al.  Structure-activity relationships of arylcyclohexylamines as discriminative stimuli in pigeons. , 1988, The Journal of pharmacology and experimental therapeutics.

[58]  P. Portoghese,et al.  Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. , 1988, The Journal of pharmacology and experimental therapeutics.

[59]  E. Domino,et al.  Sigma and Phencyclidine: Like Compounds As Molecular Probes in Biology , 1988 .

[60]  E. London,et al.  Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. , 1988, Science.

[61]  L. Dykstra,et al.  Discriminative stimulus effects of N-allylnormetazocine in rats trained to discriminate a kappa from a sigma agonist. , 1987, Life sciences.

[62]  C. Haertzen,et al.  Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. , 1986, The Journal of pharmacology and experimental therapeutics.

[63]  L. Iversen,et al.  The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[64]  H. Emrich,et al.  Psychotomimesis mediated by kappa opiate receptors , 1986, Science.

[65]  S. Snyder,et al.  Pharmacological and autoradiographic discrimination of sigma and phencyclidine receptor binding sites in brain with (+)-[3H]SKF 10,047, (+)-[3H]-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine and [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine. , 1986, The Journal of pharmacology and experimental therapeutics.

[66]  K. Rice,et al.  Differentiation of [3H]phencyclidine and ( + )‐[3H]SKF‐10,047 binding sites in rat cerebral cortex , 1985, FEBS letters.

[67]  B. Johnson,et al.  Sigma opioid receptor: characterization and co-identity with the phencyclidine receptor. , 1985, The Journal of pharmacology and experimental therapeutics.

[68]  S. Tam,et al.  (+)-[^3H]SKF-10,047, (+)[^3H]ethylketocyclazocine, μ,κ,δ and phencyclidine binding sites in guinea pig brain membranes , 1985 .

[69]  E. J. Simon,et al.  Characterization of specific binding sites for [3H](d)-N-allylnormetazocine in rat brain membranes. , 1985, Molecular pharmacology.

[70]  S. Tam,et al.  Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[71]  J. Stonham,et al.  The Effect of Naloxone on Pentazocine Induced Hallucinations , 1984, Journal of the Royal Army Medical Corps.

[72]  A. H. Tang,et al.  Discriminative stimulus properties of nalorphine in the rhesus monkeys. , 1983, The Journal of pharmacology and experimental therapeutics.

[73]  S. Tam.  Naloxone-inaccessible sigma receptor in rat central nervous system. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[74]  A. Tomie,et al.  Effects of SKF-10047 in the phencyclidine-dependent rat: evidence for common receptor mechanisms. , 1983, Drug and alcohol dependence.

[75]  T. Su.  Evidence for sigma opioid receptor: binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. , 1982, The Journal of pharmacology and experimental therapeutics.

[76]  H. Shannon.  Phencyclidine-like discriminative stimuli of (+)- and (-)-N-allylnormetazocine in rats. , 1982, European journal of pharmacology.

[77]  A. Herz,et al.  Non-opioid psychotomimetic-like discriminative stimulus properties of N-allylnormetazocine (SKF 10,047) in the rat. , 1982, European journal of pharmacology.

[78]  K. Brady,et al.  Stereoisomers of N-allylnormetazocine: phencyclidine-like behavioral effects in squirrel monkeys and rats. , 1982, Science.

[79]  R. Zukin,et al.  Demonstration of [3H]cyclazocine binding to multiple opiate receptor sites. , 1981, Molecular pharmacology.

[80]  H. Merz,et al.  N-[(Tetrahydrofuryl)alkyl] and N-(alkoxyalkyl) derivatives of (-)-normetazocine, compounds with differentiated opioid action profiles. , 1979, Journal of medicinal chemistry.

[81]  C. Coursey.  The Psychotomimetic Side Effects of Pentazocine , 1978 .

[82]  W. Beaver,et al.  Twin Crossover Relative Potency Analgesic Assays in Man. II. Morphine Vs. 8‐Methoxycyclazocine , 1977, Journal of clinical pharmacology.

[83]  W. Beaver,et al.  Twin Crossover Relative Potency Analgesic Assays in Man. I. Morphine Vs. Morphine , 1977, Journal of clinical pharmacology.

[84]  J. Thompson,et al.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. , 1976, The Journal of pharmacology and experimental therapeutics.

[85]  W. Forrest,et al.  Analgesic and other effects of the d‐ and l‐isomers of pentazocine , 1969, Clinical pharmacology and therapeutics.

[86]  D. Jasinski,et al.  Antagonism of the subjective, behavioral, pupillary, and respiratory depressant effects of cyclazocine by naloxone , 1968, Clinical pharmacology and therapeutics.

[87]  L. Lasagna,et al.  THE ANALGESIC EFFICACY AND RESPIRATORY EFFECTS IN MAN OF A BENZOMORPHAN "NARCOTIC ANTAGONIST" , 1964 .

[88]  A. Keats,et al.  Narcotic Antagonists as Analgesics: Clinical Aspects , 1964 .

[89]  L. Harris,et al.  Narcotic Antagonists as Analgesics , 1962, Science.

[90]  A. Keats,et al.  Subjective effects of nalorphine in hospitalized patients. , 1957, The Journal of pharmacology and experimental therapeutics.

[91]  R. Huggins,et al.  SOME EFFECTS OF N–ALLYLNORMORPHINE ON NORMAL SUBJECTS AND A REVIEW OF THE LITERATURE , 1955, Anesthesiology.

[92]  L. Lasagna,et al.  The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man. , 1954, The Journal of pharmacology and experimental therapeutics.

[93]  L. Lasagna.  Nalorphine (n-allylnormorphine); practical and theoretical considerations. , 1954, A.M.A. archives of internal medicine.

[94]  A. Wikler,et al.  N-Allylnormorphine: effects of single doses and precipitation of acute abstinence syndromes during addiction to morphine; methadone or heroin in man (post addicts). , 1953, The Journal of pharmacology and experimental therapeutics.